Destiny Pharma
      
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • Our Values
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News and Media
    • Media
    • Events
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Careers
  • Contact

Archive 2014

2014
  • - 19 Dec 2014 – Drug-resistant superbugs could cost up to $100 trillion and cause 10 million extra deaths a year by 2050
  • - 05 Dec 2014 – Destiny Pharma invited to attend the first event of the Review on Antimicrobial Resistance Meeting chaired by Jim O’Neill and hosted by the Wellcome Trust on the 11th December 2014
  • - 17 Nov 2014 – Antibiotic Awareness Day
  • - 01 Oct 2014 – Destiny Pharma to attend IDWeek in Philadelphia, PA
  • - 29 Sep 2014 – Obama Administration Takes Actions to Combat Antibiotic-Resistant Bacteria
  • - 04 Sep 14 – Destiny Pharma to attend 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Conference in Washington DC
  • - 04 Aug 2014 – Angel CoFund join UK investors in £2.8m investment for Superbug Killing Company
  • - 01 Jul 2014 – David Cameron says that superbugs can cast “world back into the dark ages of medicine”
  • - 01 Apr 2014 – Destiny Pharma to attend 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Conference in Barcelona, Spain
  • - 01 Jan 2014 – January 2014: ADAPT Act to Spur Antibiotic Development

Archive

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement